{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-004995","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.055848+00:00","generated_at":"2026-05-16T03:04:57.015597+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio reports positive Phase 3 infigratinib results in achondroplasia; NDA/MAA planned H2 2026","bullets":["PROPEL 3 met primary endpoint: change from baseline in AHV at Week 52 (p<0.0001); mean treatment difference +2.10 cm/year.","First statistically significant improvement in body proportionality vs placebo in children <8 years (LS mean -0.05, p<0.05).","Key secondary endpoint height Z-score (achondroplasia reference) LS mean increase +0.41 SD on treatment (p<0.0001).","No discontinuations or serious AEs related to study drug; 3 cases (4%) mild transient hyperphosphatemia, no FGFR1/2 AEs.","NDA and MAA submissions for achondroplasia planned in second half of 2026; accelerate hypochondroplasia development."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-004995","json":"https://secwatch.observer/filing/0001140361-26-004995.json","markdown":"https://secwatch.observer/filing/0001140361-26-004995.md","text":"https://secwatch.observer/filing/0001140361-26-004995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/0001140361-26-004995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126004995/ef20065539_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:04:57.015597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}